Get the Stockscreener App
219.35
0.09%
-0.20
Cidara Therapeutics Inc stock is traded at $219.35, with a volume of 1.31M.
It is down -0.09% in the last 24 hours and up +112.51% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$219.55
Open:
$219.45
24h Volume:
1.31M
Relative Volume:
1.02
Market Cap:
$6.90B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
-19.71
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
+0.75%
1M Performance:
+112.51%
6M Performance:
+735.62%
1Y Performance:
+1,157%
1-Day Range:
$218.86
$219.90
1-Week Range:
$217.41
$220.41
52-Week Range:
$15.22
$220.41
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
219.35 | 6.90B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-17-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-17-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-16-25 | Initiated | Morgan Stanley | Overweight |
| Oct-10-25 | Initiated | JP Morgan | Overweight |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Analysts Shift to Hold as Cidara’s (CDTX) Recent Acquisition Deal Caps Upside - MSN
Top Biotech Stocks To Watch TodayNovember 21st - MarketBeat
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck - Cheboygan Daily Tribune
10 Hottest SMID-Cap Stocks So Far In 2025 - Insider Monkey
Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Promising Biotech Stocks To ConsiderNovember 18th - MarketBeat
Promising Mid Cap Stocks To ConsiderNovember 17th - MarketBeat
(CDTX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Top Biotech Stocks To ConsiderNovember 20th - MarketBeat
Jefferies 25: Merck’s Cidara Buyout Could Help Meet Needs Of Increasingly Vaccine-Hesitant US - Citeline News & Insights
Merck Invests $9.2B in Cidara to Boost Breakthrough Flu Drug - BUCKSCO.Today
Can Cidara Therapeutics Inc. stock surprise with earnings upside2025 Market Sentiment & Free Safe Entry Trade Signal Reports - newser.com
Will Cidara Therapeutics Inc. (20D0) stock hit Wall Street targetsWeekly Stock Report & Risk Controlled Swing Alerts - newser.com
Will Cidara Therapeutics Inc. stock deliver long term returnsWeekly Gains Report & Smart Money Movement Tracker - newser.com
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer - AOL.com
Why Cidara Therapeutics Inc. stock could benefit from AI revolution2025 Winners & Losers & Verified Technical Signals - newser.com
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? - Finviz
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. - Yahoo Finance
Merck deal shows potential of strain-agnostic flu protection - The Pharma Letter
Should you wait for a breakout in Cidara Therapeutics Inc.Market Risk Analysis & Short-Term High Return Ideas - newser.com
What to do if you’re stuck in Cidara Therapeutics Inc.Trend Reversal & Reliable Entry Point Alerts - newser.com
Will Cidara Therapeutics Inc. stock outperform international peersChart Signals & AI Optimized Trading Strategy Guides - newser.com
Is Cidara Therapeutics Inc. stock poised for growthEarnings Risk Report & Free Real-Time Volume Trigger Notifications - newser.com
Best Mid Cap Stocks To Add to Your WatchlistNovember 14th - MarketBeat
Using data models to predict Cidara Therapeutics Inc. stock movementMarket Performance Recap & Safe Entry Momentum Tips - newser.com
Merck's Cidara Buyout Is An Opportunistic Win For Both PartiesHere's Why (NASDAQ:CDTX) - Seeking Alpha
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara ... - Black Hills Pioneer
Live market analysis of Cidara Therapeutics Inc.July 2025 Final Week & Risk Managed Investment Signals - newser.com
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):